


PATENT
Customer No. 22,852
Attorney Docket No. 03715.0152



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Claude AURIAULT et al.

Application No.: 10/566,386

Filed: January 30, 2006

National Stage of: PCT/IB2004/002374

For: TRANSGENIC MICE HAVING A HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) PHENOTYPE, EXPERIMENTAL USES AND APPLICATIONS

Group Art Unit: Unassigned

Examiner: Unassigned

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed non-patent literature documents are enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application. If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,


FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: July 7, 2006

By: 

Kenneth J. Meyers
Reg. No. 25,146
Tel.: 202-408-4033
Fax: 202-408-4400
Email: ken.meyers@finnegan.com

IDS Form PTO/SB/08: Substitute for form 1449A/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/566,386
				Filing Date	January 30, 2006
				First Named Inventor	Claude AURIAULT
				Art Unit	Not Assigned
				Examiner Name	Not Assigned
				Attorney Docket Number	03715.0152-00000
Sheet	1	of	1		



U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		ABEL URETA-VIDAL et al., Phenotypical and Functional Characterization of the CD8 ⁺ T Cell Repertoire of HLA-A2.1 Transgenic, H-2K ^b D ^b Double Knockout Mice, Journal of Immunology, 1999, American Association of Immunologists, pp. 2555-2560	
		HÜSEYİN FIRAT et al., Comparative analysis of the CD8 ⁺ T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice, 2002 the Japanese Society for Immunology, International Immunology, Vol. 14, No. 8, pp. 925-934	
		PIERRE-SIMON ROHRLICH et al., HLA-B*0702 transgenic, H-2K ^b D ^b double-knockout mice: phenotypical and functional characterization in response to influenza virus, 2003 the Japanese Society for Immunology, International Immunology, Vol. 15, No. 6, pp. 765-772	
		S. CHENG et al., Characterization of HLA DR2 and DQ8 transgenic mouse with a new engineered mouse class II deletion, which lacks all endogenous class II genes, Journal of Autoimmunity 21 (2003) 195-199	
Examiner Signature			Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.